Dr. Dunn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
White 502
Boston, MA 02114Phone+1 617-726-4922
Summary
- I am a faculty member in the Department of Neurological Surgery with an appointment in the Department of Pathology and Immunology at Washington University, where I am a member of the newly established interdisciplinary Center for Human Immunology and Immunotherapy Programs. I oversee a research program focused on the immunobiology of malignant glioma with the goal of translational and clinical trial efforts in the treatment of this disease. Whereas extensive genomic profiling is uncovering tumor cell vulnerabilities across many cancer types, this paradigm has not extended to glioblastoma due, at least in part, to the tremendous heterogeneity within these tumors. In contrast to conventional targeted therapeutic approaches, immune-based strategies may be particularly well-suited to treating these tumors due to the incredible diversity of antigens recognizable by immune cells.
My laboratory is focused on understanding the molecular and cellular basis of the immune response to glioblastoma in preclinical and translational settings as well as clarifying the relationships between glioma genomics and immunogenicity, an area termed “cancer immunogenomics.” These investigations are complemented by ongoing clinical trial efforts in this area.
Education & Training
- Massachusetts General HospitalResidency, Neurological Surgery, 2006 - 2013
- Massachusetts General HospitalResidency, Surgery, 2006 - 2007
- Washington University School of Medicine in St. LouisPhD, Pathology and Immunology, 1998 - 2006
- Washington University in St. Louis School of MedicineClass of 2006, MD
Certifications & Licensure
- ME State Medical License Current
- MA State Medical License 2011 - 2026
- MO State Medical License 2014 - 2025
- NH State Medical License 2023 - 2025
- IL State Medical License 2021 - 2023
- American Board of Neurological Surgery Neurological Surgery
Clinical Trials
- Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Start of enrollment: 2018 Oct 31
- Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma Start of enrollment: 2020 Jul 14
- Mapping Draining Lymph Nodes in CNS Malignancies Start of enrollment: 2019 Dec 03
- Join now to see all
Publications & Presentations
PubMed
- 447 citationsA critical function for type I interferons in cancer immunoeditingGavin P. Dunn, Allen T. Bruce, Kathleen C. F. Sheehan, Vijay Shankaran, Ravindra Uppaluri
Nature Immunology. 2005-06-12 - 1148 citationsInterferons, immunity and cancer immunoediting.Gavin P. Dunn, Catherine M. Koebel, Robert D. Schreiber
Nature Reviews. Immunology. 2006-11-01 - 74 citationsConsumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress.Susan J. Gelman, Fuad J. Naser, Nathaniel G. Mahieu, Lisa D. McKenzie, Gavin P. Dunn
Cell Reports. 2018-01-09
Journal Articles
- A Deep Learning Approach to Automate Refinement of Somatic Variant Calling from Cancer Sequencing DataRavindra Uppaluri, Gavin P Dunn, Ramaswamy Govindan, S Joshua Swamidass, Todd A Fehniger, Nature
Press Mentions
- ASCO21 Preview - Equity: Every Patient. Every Day. EverywhereMay 27th, 2021
- Brain Tumor Awareness Month: 2021 Immunotherapy Research UpdatesMay 5th, 2021
- Current Trends in Cancer ImmunotherapyDecember 17th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: